Summary
Background Multisystem inflammatory syndrome in children (MIS-C) is a severe post-acute sequela of SARS-CoV-2 infection. The highly diverse clinical features of MIS-C necessities characterizing its features by subphenotypes for improved recognition and treatment. However, jointly identifying subphenotypes in multi-site settings can be challenging. We propose a distributed multi-site latent class analysis (dMLCA) approach to jointly learn MIS-C subphenotypes using data across multiple institutions.
Methods We used data from the electronic health records (EHR) systems across nine U.S. children’s hospitals. Among the 3,549,894 patients, we extracted 864 patients < 21 years of age who had received a diagnosis of MIS-C during an inpatient stay or up to one day before admission. Using MIS-C conditions, laboratory results, and procedure information as input features for the patients, we applied our dMLCA algorithm and identified three MIS-C subphenotypes. As validation, we characterized and compared more granular features across subphenotypes. To evaluate the specificity of the identified subphenotypes, we further compared them with the general subphenotypes identified in the COVID-19 infected patients.
Findings Subphenotype 1 (46.1%) represents patients with a mild manifestation of MIS-C not requiring intensive care, with minimal cardiac involvement. Subphenotype 2 (25.3%) is associated with a high risk of shock, cardiac and renal involvement, and an intermediate risk of respiratory symptoms. Subphenotype 3 (28.6%) represents patients requiring intensive care, with a high risk of shock and cardiac involvement, accompanied by a high risk of >4 organ system being impacted. Importantly, for hospital-specific clinical decision-making, our algorithm also revealed a substantial heterogeneity in relative proportions of these three subtypes across hospitals. Properly accounting for such heterogeneity can lead to accurate characterization of the subphenotypes at the patient-level.
Interpretation Our identified three MIS-C subphenotypes have profound implications for personalized treatment strategies, potentially influencing clinical outcomes. Further, the proposed algorithm facilitates federated subphenotyping while accounting for the heterogeneity across hospitals.
Evidence before this study Before undertaking this study, we searched PubMed and preprint articles from in early 2022 for studies published in English that investigated the clinical subphenotypes of MIS-C using the terms “multi-system inflammatory syndrome in children” or “pediatric inflammatory multisystem syndrome”, and “phenotypes”. One study in 2020 divided 63 patients into Kawasaki and non-Kawasaki disease subphenotypes. Another CDC study in 2020 evaluated 3 subclasses of MIS-C in 570 children, with one class representing the highest number of organ systems, a second class with predominant respiratory system involvement, and a third class with features overlapping with Kawasaki Disease. However, both studies were conducted during the early phase of the pandemic when misclassification of cases as Kawasaki disease or acute COVID-19 may have occurred. Therefore, the subphenotypes of MIS-C needs further investigation. In addition, we searched research articles for studies published in English on algorithms for distributed multi-site latent class analysis with the terms “distributed latent class analysis” or “multi-site latent class analysis”. Most of the existing literatures for distributed learning have focused on supervised learning. Literatures discuss latent class analysis for disease sub phenotyping in a multi-site setting where data are distributed across different sites are lacking.
Added value of this study We developed a new algorithm to jointly identify subphenotypes of MIS-C using data across multiple institutions. Our algorithm does not require individual-level data sharing across the institutions while achieves the same result as when the data are pooled. Besides, our algorithm properly accounts for the heterogeneity across sites, and it can lead to accurate characterization of the subphenotypes at the patient-level. We then applied our algorithm to PEDSnet data for identifying the subphenotypes of MIS-C. PEDSnet provides one of the largest MIS-C cohorts described so far, providing sufficient power for detailed analyses on MIS-C subphenotypes. We identified three subphenotypes that can be characterized as mild with minimal cardiac involvement (46.1%), severe requiring intensive care with >4 organ being impacted, and the one with intermediate risk of respiratory symptoms, and high risk of shock, cardiac and renal involvement (25.3%). For hospital-specific clinical decision-making, our algorithm revealed a substantial heterogeneity in relative proportions of these three subtypes across hospitals.
Implications of all the available evidence Our algorithm provides an effective distributed learning framework for disease subphenotyping using multi-site data based on aggregated data only. It facilitates high accuracy while properly accounts for the between-site heterogeneity. The results provide an update to the subphenotypes of MIS-C with larger and more recent data, aid in the understanding of the various disease patterns of MIS-C, and may improve the evaluation and intervention of MIS-C.
Competing Interest Statement
Dr. Mejias reports funding from Janssen, Merck for research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr. Rao reports prior grant support from GSK and Biofire. Dr. Chen receives consulting support from GSK. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend from Elsevier. All other authors have no conflicts of interest to disclose.
Funding Statement
This study is part of the NIH RECOVER Initiative, which seeks to understand, treat, and prevent the post-acute sequelae of SARS-CoV-2 infection (PASC). For more information on RECOVER, visit https://recovercovid.org/. This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research. This work was supported partially through a Patient-Centered Outcomes Research Institute (PCORI) Project Program Award (ME-2019C3-18315, NJ, XL, QW and YC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of data was approved by the Childrens Hospital of Philadelphias Institutional Review Board (IRB). The informed consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵^ Co-first authors
Data Availability
The data is not publicly available due to privacy concerns. The individual de-identified participant data will not be shared. The data that support the findings of this study may be available through request and DUA process to the corresponding authors.
